Wall Street brokerages expect Portola Pharmaceuticals Inc (NASDAQ:PTLA) to report earnings per share (EPS) of ($1.05) for the current quarter, according to Zacks. Two analysts have issued estimates for Portola Pharmaceuticals’ earnings, with estimates ranging from ($1.12) to ($0.96). Portola Pharmaceuticals reported earnings per share of ($1.61) during the same quarter last year, which suggests a positive year-over-year growth rate of 34.8%. The company is expected to announce its next earnings report on Thursday, August 8th.
On average, analysts expect that Portola Pharmaceuticals will report full year earnings of ($4.13) per share for the current fiscal year, with EPS estimates ranging from ($4.20) to ($4.00). For the next financial year, analysts expect that the company will post earnings of ($2.63) per share, with EPS estimates ranging from ($2.83) to ($2.35). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Portola Pharmaceuticals.
Portola Pharmaceuticals (NASDAQ:PTLA) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($1.02). The firm had revenue of $22.17 million during the quarter, compared to the consensus estimate of $20.60 million. Portola Pharmaceuticals had a negative net margin of 618.46% and a negative return on equity of 238.48%. The company’s revenue was up 233.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.28) EPS.
PTLA opened at $26.27 on Friday. The company has a market cap of $1.79 billion, a P/E ratio of -5.24 and a beta of 2.43. Portola Pharmaceuticals has a 1 year low of $14.81 and a 1 year high of $44.25. The company has a debt-to-equity ratio of 5.15, a current ratio of 4.81 and a quick ratio of 4.77.
In other Portola Pharmaceuticals news, CFO Mardi Dier sold 40,486 shares of the stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $37.39, for a total value of $1,513,771.54. Following the completion of the sale, the chief financial officer now owns 66,733 shares of the company’s stock, valued at $2,495,146.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Hollings Renton sold 5,000 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $34.45, for a total transaction of $172,250.00. Following the completion of the sale, the director now directly owns 14,000 shares of the company’s stock, valued at approximately $482,300. The disclosure for this sale can be found here. 4.50% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of the business. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Portola Pharmaceuticals by 7.0% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 8,190 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 538 shares during the last quarter. Strs Ohio boosted its stake in shares of Portola Pharmaceuticals by 1.3% during the 1st quarter. Strs Ohio now owns 45,600 shares of the biopharmaceutical company’s stock valued at $1,582,000 after buying an additional 600 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its stake in shares of Portola Pharmaceuticals by 2.2% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 33,127 shares of the biopharmaceutical company’s stock valued at $647,000 after buying an additional 719 shares during the last quarter. Icon Wealth Partners LLC purchased a new position in shares of Portola Pharmaceuticals during the 1st quarter valued at approximately $26,000. Finally, FTB Advisors Inc. purchased a new position in shares of Portola Pharmaceuticals during the 1st quarter valued at approximately $33,000.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Featured Article: What factors cause inflation to rise?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.